All publications

Export 169 results:
Author [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Stirrup O, Asboe D, Pozniak A, Sabin C, Gilson R, Mackie N, Dunn D, Cohort UKHIVDrug R.  2019.  Use of emtricitabine or lamivudine following detection of the M184V/I HIV-1 resistance mutation. 23rd International Workshop on HIV and Hepatitis Observational Databases.
Gifford RJM, Pillay D, UK HIV Drug Resistance Database.  2005.  Utilisation of HIV-1 subtype specific consensus sequences to explore treatment related mutational patterns within and between subtypes. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, O’Shea S, Tong W, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2013.  Viral genotype in subtype C significantly influences plasma viral load. 20th International HIV Dynamics & Evolution Conference, 8-11 May 2013.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2013.  Viral Genotype in Subtype C Significantly Influences Plasma Viral Load. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.
Grover D, Allen L, Pillay D, Green H, Copas A, Forsyth S, Edwards SG, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2005.  Virological and clinical outcomes in patients with multi (three)-class drug resistance (MDR). 11th Annual Conference of the British HIV Association, 20-23 April 2005.
Jose S., Quinn K., Dunn DT, Cox A., Sabin CA, Fidler S.  2016.  Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. HIV Med. 17:368-72.
Gupta R.K, Hill A., Sawyer A.W, Cozzi-Lepri A, von Wyl V., Yerly S, Lima V.D, Günthard HF, Gilks C., Pillay D.  2009.  Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 9:409-17.
Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C, Dunn DT.  2018.  Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.. J Antimicrob Chemother.
Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin CA, Phillips AN, Allen E., Pillay D.  2008.  What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother. 61:705-13.